Table 2. Chemotherapy.
| Chemotherapy | GCT: study group (n=100) | GCT: validation group (n=77) | Non-GCT neoplasms: control group (n=100) |
|---|---|---|---|
| Regimen | |||
| BEP | 46 (46%) | 46 (60%) | |
| EP | 42 (42%) | 28 (36%) | |
| CISCA-VB | 12 (12%) | 3 (4%) | |
| API-AI | 31 (31%) | ||
| Drugs | |||
| Cisplatin | 100 (100%) | 77 (100%) | 100 (100%) |
| Etoposide | 88 (88%) | 74 (96%) | 11 (11%) |
| Bleomycin | 58 (58%) | 49 (63%) | 4 (4%) |
| Doxorubicin | 12 (12%) | 3 (4%) | 31 (31%) |
| Cyclophosphamide | 12 (12%) | 3 (4%) | 1 (1%) |
| Vinblastine | 12 (12%) | 3 (4%) | 5 (5%) |
| Ifosfamide | 36 (36%) | ||
| Epirubicine | 11 (11%) | ||
| Vinorelbine | 8 (8%) | ||
| 5-Fluorouracil | 7 (7%) | ||
| α-Interferon | 2 (2%) | ||
| Thiotepa | 1 (1%) | ||
| Docetaxel | 1 (1%) | ||
| Interleukin-2 | 1 (1%) | ||
| Mitomycin C | 1 (1%) | ||
| Duration of chemotherapy (days) | 63 (6–408) | 68 (4–129) | 51 (3–258) |
| Neutropenic fever | 19 (19%) | 24 (33%) | 16 (16%) |
| Postchemotherapy surgery | 39 (39%) | 40 (52%) | 39 (39%) |
CGT=germ-cell tumours.